JNJ Stock Recent News

NEW YORK--(BUSINESS WIRE)--Today at 5pm ET is the final deadline for tens of thousands of ovarian cancer victims or their representatives to vote on the approximately $8 billion Johnson & Johnson (“J&J”) (NYSE: JNJ) talcum powder settlement, leaving claimants just hours to act. Talc claimants can vote on the plan at www.OfficialTalcClaims.com or by calling 1-888-431-4056. The approximately $8 billion plan, which has a net present value of $6.475 billion, will compensate current and futu.

If approved, Yuvanci® would become the only single tablet combination for treatment for patients with PAH Johnson & Johnson's comprehensive PAH portfolio has the potential to cover all guideline-recommended treatment pathways BEERSE, BELGIUM, July 26, 2024 (GLOBE NEWSWIRE) --  Janssen-Cilag International NV, a Johnson & Johnson company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the Marketing Authorisation (MA) of Yuvanci®. Yuvanci® is a single tablet combination therapy of macitentan 10 mg and tadalafil 40 mg (M/T STCT) as a substitution therapy for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, who are already treated with the combination of macitentan and tadalafil given concurrently as separate tablets.1 PAH is a rare, progressive and life-threatening disease characterised by the constriction of small pulmonary ar

Though J&J (JNJ) beat estimates for both earnings and sales in the second quarter, a new investor should avoid buying the stock right now due to its legal troubles.

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Johnson & Johnson might be the worst performing big pharma stock YTD, but there's upside possible for it in the remainder of 2024. Revenue growth guidance was upgraded and even with a downgrade in EPS guidance, the number is still expected to see a YoY increase. Its market multiples indicate the possibility of some uptick, and there are dividends to consider too.

Johnson & Johnson, the pharmaceutical giant with a 3.21% dividend yield, released financial results for Q2 2024 that exceeded my expectations. Its oncology franchise revenue was $5.09 billion for the three months ended June 30, 2024, an increase of 15.7% year-on-year. For example, sales of Darzalex, an anticancer medication, were $2.88 billion in the second quarter of 2024, up 18.4% year-on-year.

Johnson & Johnson (NYSE: JNJ) recently reported its Q2 results, with revenues aligning and earnings exceeding our estimates. The company reported revenue of $22.4 billion and adjusted earnings of $2.82 per share, compared to our estimates of $22.5 billion and $2.72, respectively.

Phase 4 SPRAVATO® monotherapy data shows rapid improvement in depressive symptoms at ~24 hours, sustained through at least 4 weeks Monotherapy submission builds on more than a decade of research, 31 clinical trials and more than five years of real-world use that reinforce the safety and efficacy of SPRAVATO® TITUSVILLE, N.J. , July 22, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of SPRAVATO® (esketamine) CIII nasal spray as a monotherapy for adults living with treatment-resistant depression (TRD).

Wednesday, Johnson & Johnson JNJ reported a second-quarter adjusted EPS of $2.82, up 10.2% Y/Y, beating the consensus of $2.70.

Johnson & Johnson JNJ reported better-than-expected second-quarter earnings on Wednesday.